{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:50:11Z","timestamp":1783785011429,"version":"3.55.0"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Low\u2010density lipoprotein apheresis (LDL\u2010A) therapy has shown reasonable efficacy in treating nephrotic syndrome (NS) refractory to initial drug therapy and has been covered by National Health Insurance for the indication of drug\u2010resistant focal segmental glomerulosclerosis (FSGS) since 1992 in Japan and has contributed to liberating substantial number of patients of this disease from entering into end\u2010stage renal disease by easier practical application in actual clinical settings. Subsequently, various beneficial evidence of this treatment has accumulated on those other than FSGS, however, due to the limitation of covered disease insurance only for FSGS, patients with diseases other than FSGS are unlikely to benefit from this treatment in practice. This review summarizes the therapeutic evidence of the beneficial effect of LDL\u2010A accumulated to date and the mechanisms of action analyzed from multifaceted perspectives. examines the applicability of expanding insurance coverage for diseases other than FSGS.<\/jats:p>","DOI":"10.1111\/1744-9987.14056","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T17:46:23Z","timestamp":1692639983000},"page":"987-999","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Updated evidence of beneficial effect of <scp>LDL<\/scp> apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval"],"prefix":"10.1111","volume":"27","author":[{"given":"Eri","family":"Muso","sequence":"first","affiliation":[{"name":"Department of Food and Nutrition, Faculty of Contemporary Home Economics Kyoto Kacho University  Kyoto Japan"},{"name":"Department of Nephrology Kitano Hospital, the Tazuke Kofukai Medical Research Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kakita","sequence":"additional","affiliation":[{"name":"Department of Nephrology Kitano Hospital, the Tazuke Kofukai Medical Research Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology Kitano Hospital, the Tazuke Kofukai Medical Research Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology Kitano Hospital, the Tazuke Kofukai Medical Research Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01864-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008303230905"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.190"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2741\/marsh"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91513-6"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0930-5"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2009.184"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.196"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00001.2002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00223.2015"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.100"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.09220.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2006.04.072"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2711"},{"key":"e_1_2_11_16_1","article-title":"Benefit effect of low\u2010density lipoprotein apheresis via modifying immune system in patients with refractory nephrotic syndrome","volume":"29","author":"Kakita H","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202462"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920060103"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07130.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3066"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020912"},{"issue":"9","key":"e_1_2_11_23_1","first-page":"1153","article-title":"Possible therapeutic application of low density lipoprotein apheresis (LDL\u2010A) in conjunction with double filtration plasmapheresis (DFPP) in drug\u2010resistant nephrotic syndrome due to focal glomerular sclerosis (FGS)","volume":"30","author":"Tojo K","year":"1988","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt1985.24.560"},{"issue":"4","key":"e_1_2_11_25_1","first-page":"345","article-title":"Correlations of C1q\u2010 and C3d\u2010bearing circulating immune complexes with immunopathological disease activity in lupus nephritis patients","volume":"36","author":"Muso E","year":"1994","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"7","key":"e_1_2_11_26_1","first-page":"1517","article-title":"LDL adsorption therapy in a case of childhood refractory nephrotic syndrome (FGS) complicated with prominent hyperlipidemia","volume":"93","author":"Hattori M","year":"1989","journal-title":"J Jpn Pediatr Soc"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP67341"},{"issue":"1","key":"e_1_2_11_28_1","first-page":"31","article-title":"Apheresis therapy in nephrotic syndrome","volume":"25","author":"Wada T","year":"2006","journal-title":"Jpn J Apher"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046112"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-014-0996-8"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000437338"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13694"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg1050"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00716.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13120"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02071-6"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S248610"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12561"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00518.x"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.7204"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02098-5"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-014-1030-x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13749"},{"key":"e_1_2_11_44_1","volume-title":"Guidelines for the treatment of internal medicine and pediatric complications after kidney transplantation","author":"Japanese Society for Clinical Renal Transplantation Guideline Preparation Committee","year":"2011"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"issue":"4","key":"e_1_2_11_46_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.14056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:26:40Z","timestamp":1706675200000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.14056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/1744-9987.14056"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.14056","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"2023-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}